ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,281.22
0.08%
Dow Jones
44,722.06
-0.31%
Gold vs US Dollar
2,637.60
0.02%
Brent Oil
72.675
0.39%
Bitcoin
94,914.60
-1.11%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. PAVmed Inc (PAVM)

  7. PAVmed Inc (PAVM) News

PAVmed (PAVM)

PAVmed Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PAVM
DateTimeSourceHeadlineSymbolCompany
20/11/202412:56PR Newswire (US)Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA TestNASDAQ:PAVMPAVmed Inc
18/11/202413:15PR Newswire (US)Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumNASDAQ:PAVMPAVmed Inc
14/11/202413:01PR Newswire (US)PAVmed Provides Business Update and Third Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
07/11/202413:01PR Newswire (US)Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed PublicationNASDAQ:PAVMPAVmed Inc
05/11/202413:01PR Newswire (US)Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue DriversNASDAQ:PAVMPAVmed Inc
31/10/202412:31PR Newswire (US)PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024NASDAQ:PAVMPAVmed Inc
30/10/202412:31PR Newswire (US)Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024NASDAQ:PAVMPAVmed Inc
15/10/202411:51PR Newswire (US)Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA TestNASDAQ:PAVMPAVmed Inc
10/10/202411:51PR Newswire (US)PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer CareNASDAQ:PAVMPAVmed Inc
09/10/202412:01PR Newswire (US)Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual SummitNASDAQ:PAVMPAVmed Inc
08/10/202411:49PR Newswire (US)Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024NASDAQ:PAVMPAVmed Inc
01/10/202412:01PR Newswire (US)Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL PlayersNASDAQ:PAVMPAVmed Inc
24/09/202412:01PR Newswire (US)American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer TestNASDAQ:PAVMPAVmed Inc
16/09/202420:30PR Newswire (US)PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing RequirementsNASDAQ:PAVMPAVmed Inc
10/09/202411:56PR Newswire (US)Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World CongressNASDAQ:PAVMPAVmed Inc
03/09/202411:51PR Newswire (US)Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile HealthNASDAQ:PAVMPAVmed Inc
20/08/202412:16PR Newswire (US)Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and CancerNASDAQ:PAVMPAVmed Inc
13/08/202412:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PAVMPAVmed Inc
13/08/202412:16PR Newswire (US)The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal CancerNASDAQ:PAVMPAVmed Inc
13/08/202412:01PR Newswire (US)PAVmed Provides Business Update and Second Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
12/08/202420:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PAVMPAVmed Inc
12/08/202412:07PR Newswire (US)Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
08/08/202412:31PR Newswire (US)Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing EventNASDAQ:PAVMPAVmed Inc
06/08/202412:15PR Newswire (US)Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer TestingNASDAQ:PAVMPAVmed Inc
05/08/202412:15PR Newswire (US)Lucid Diagnostics to Participate in Upcoming Investor ConferencesNASDAQ:PAVMPAVmed Inc
30/07/202412:15PR Newswire (US)PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024NASDAQ:PAVMPAVmed Inc
29/07/202412:15PR Newswire (US)Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024NASDAQ:PAVMPAVmed Inc
23/07/202412:01PR Newswire (US)Lucid Diagnostics Announces Record Quarterly EsoGuard® Test VolumeNASDAQ:PAVMPAVmed Inc
11/07/202412:31PR Newswire (US)Lucid Diagnostics Launches New Corporate WebsiteNASDAQ:PAVMPAVmed Inc
02/07/202411:55PR Newswire (US)Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening PopulationNASDAQ:PAVMPAVmed Inc
 Showing the most relevant articles for your search:NASDAQ:PAVM

Your Recent History

NASDAQ
JAGX
Jaguar Health
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Level 2 Lite

    1 year 35%, 2 years 45% and *3 years 60%

    *Across 3 years £2132.64 only £853.06